- Enbumyst™ is the first FDA-approved intranasal loop diuretic for edema treatment.
- It offers a 33% faster absorption compared to oral administration.
- Aptar's Unidose System is used for systemic drug absorption via nasal mucosa.
FDA Approval
Aptar Pharma's Unidose Liquid System is the delivery method for Enbumyst™ (Bumetanide Nasal Spray) 0.5mg, recently approved by the U.S. FDA. This marks the first intranasal loop diuretic for treating edema related to congestive heart failure, hepatic, and renal disease, including nephrotic syndrome in adults.
Advantages of Enbumyst™
Enbumyst™ offers a convenient, self-administered alternative to traditional oral and intravenous forms, focusing on outpatient therapy. Clinical data shows a faster onset of sodium excretion and a 33% increase in absorption speed compared to oral administration.
Unidose System
The therapy utilizes Aptar Pharma’s Unidose System, a single-use nasal delivery system designed for systemic drug absorption via the nasal mucosa. This system is already used in over 30 U.S. FDA and EMA-approved therapies, known for its reliability and ease of use.
